teprotumumab sold brand name tepezza medication used treat adults thyroid eye disease rare condition muscles fatty tissues behind eye become inflamed causing eyes bulge common side effects muscle spasm nausea hair loss diarrhea fatigue high blood sugar hearing loss dry skin altered sense taste teprotumumab used pregnant women childbearing potential pregnancy status verified prior beginning treatment counseled pregnancy prevention treatment six months following last human monoclonal antibody developed genmab tumour treatment later researched river vision development corporation horizon therapeutics used ophthalmic binds teprotumumab approved use united states january us food drug administration fda considers firstinclass multicenter randomized trial patients active graves ophthalmopathy teprotumumab effective february horizon announced results phase iii confirmatory trial evaluating teprotumumab treatment active thyroid eye disease ted study met primary endpoint showing patients treated teprotumumab compared placebo meaningful improvement proptosis bulging eye teprotumumab patients compared placebo patients achieved primary endpoint mm reduction proptosis proptosis main cause morbidity ted secondary endpoints also met safety profile consistent phase ii study teprotumumab july horizon submitted biologics license application fda teprotumumab treatment active thyroid eye disease horizon requested priority review application granted fda review period decide would result maximum review teprotumumabtrbw approved use united states january treatment adults thyroid eye disease teprotumumab first investigated treatment solid hematologic tumors including breast cancer hodgkins nonhodgkins lymphoma nonsmall cell lung cancer although results phase early phase ii trials showed promise research indications discontinued roche phase ii trials still progress allowed complete development halted due business prioritization rather safety concerns teprotumumab subsequently licensed river vision development corporation research treatment ophthalmic conditions horizon pharma horizon therapeutics horizon acquired rvdc continue clinical phase iii trials graves ophthalmopathy ted phase diabetic macular granted breakthrough therapy orphan drug status fast track designations fda graves teprotumumabtrbw approved based results two clinical trials trial trial subjects active ted randomized either receive teprotumumabtrbw subjects administered tepezza study study demonstrated greater mm reduction proptosis eye protrusion compared subjects received placebo trials conducted sites europe united fda granted application teprotumumabtrbw fasttrack designation breakthrough therapy designation priority review designation orphan drug fda granted approval tepezza horizon therapeutics ireland httpsenwikipediaorgwikiteprotumumab